Abstract |
Virotherapy using oncolytic vaccinia virus strains is one of the most promising new strategies for cancer therapy. In the current study, we analyzed the therapeutic efficacy of the oncolytic vaccinia virus GLV-1h68 against two human prostate cancer cell lines DU-145 and PC-3 in cell culture and in tumor xenograft models. By viral proliferation assays and cell survival tests, we demonstrated that GLV-1h68 was able to infect, replicate in, and lyse these prostate cancer cells in culture. In DU-145 and PC-3 tumor xenograft models, a single intravenous injection with GLV-1h68 resulted in a significant reduction of primary tumor size. In addition, the GLV-1h68-infection led to strong inflammatory and oncolytic effects resulting in drastic reduction of regional lymph nodes with PC-3 metastases. Our data documented that the GLV-1h68 virus has a great potential for treatment of human prostate carcinoma.
|
Authors | Ivaylo Gentschev, Ulrike Donat, Elisabeth Hofmann, Stephanie Weibel, Marion Adelfinger, Viktoria Raab, Martin Heisig, Nanhai Chen, Yong A Yu, Jochen Stritzker, Aladar A Szalay |
Journal | Journal of biomedicine & biotechnology
(J Biomed Biotechnol)
Vol. 2010
Pg. 489759
( 2010)
ISSN: 1110-7251 [Electronic] United States |
PMID | 20379368
(Publication Type: Journal Article)
|
Chemical References |
- Antigens, Neoplasm
- Histocompatibility Antigens Class II
- Neoplasm Proteins
|
Topics |
- Animals
- Antigens, Neoplasm
(metabolism)
- Cell Death
- Cell Line, Tumor
- Histocompatibility Antigens Class II
(immunology)
- Humans
- Lymphatic Metastasis
(pathology)
- Lymphocytes, Tumor-Infiltrating
(immunology)
- Male
- Mice
- Mice, Nude
- Neoplasm Proteins
(metabolism)
- Oncolytic Virotherapy
(methods)
- Oncolytic Viruses
(physiology)
- Prostatic Neoplasms
(immunology, pathology, therapy, virology)
- Recombination, Genetic
(genetics)
- Remission Induction
- Vaccinia virus
(physiology)
- Virus Replication
(physiology)
- Xenograft Model Antitumor Assays
|